image: Register here to join Alex Zhavoronkov PhD, Founder and CEO of Insilico Medicine, and get a deep dive into a series of AI breakthroughs and new product demos.
Credit: Insilico Medicine
Since the debut of PandaOmics and Chemistry42 in 2020 as generative AI tools for drug discovery across target discovery and molecule generation, Insilico Medicine has been periodically sharing technological updates of its proprietary Pharma.AI platform. Our latest update included the integration of AI agents, Large Language Models (LLMs), hardware solutions and customized model training functions, and as the platform continues to grow with new enhancements, we are happy to share new features in the upcoming Pharma.AI Day webinar.
Cambridge, MA, April 18— Insilico Medicine(“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, is proud to announce Pharma.AI Day 2025, the brand-new quarterly update series for Pharma.AI, scheduled on April 24, 10:00-11:00 AM EST. Register here to join Alex Zhavoronkov PhD, Founder and CEO of Insilico Medicine, and get a deep dive into a series of AI breakthroughs and new product demos.
The latest version of PandaOmics, the precision target discovery engine, now includes SSO and support of genetic data. Our latest updates to Generative Biologics, the de novo protein engineering platform, includes enhanced specification in both peptide generation and optimization. New capabilities of our Life Star1, an AI platform-guided automatic laboratory, will also be presented.
Our Large Language of Life Models (LLLMs), known as the PreciousGPT series, have gone through in-depth enhancements and fine-tuning since Precious3GPT was first open sourced in July, 2024, currently featuring natural geroprotector discovery and automated screening functions.
Our generative chemistry platform is even more powerful thanks to the latest version of Retrosynthesis, the synthetic route prediction module that is now a part of Chemistry42, and Nach01, the multimodal natural & chemical languages foundation model.
We will also showcase the latest version of Science42: Dora, the AI agent-based writing assistant with updates including more comprehensive document templates and advanced AI tools integration.
In 2016, Insilico first described the concept of using generative AI for the design of novel molecules in a peer-reviewed journal, which laid the foundation for the commercially available Pharma.AI platform, which empowered the nomination of 22 developmental/preclinical candidates (DC/PCC) in its comprehensive portfolio of over 30 assets since 2021. According to the recent key timeline benchmarks for internal DC programs from 2021 to 2024, the average time to DC is 12-18 months, with 60-200 molecules synthesized and tested per program.
About Insilico Medicine
Insilico Medicine, a globally pioneering tech-bio company powered by generative AI, utilizes its proprietary Pharma.AI platform and cutting-stage automated laboratory to accelerate drug discovery and advance innovations in life sciences research. By integrating the technologies of AI and automation, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Ten molecules in Insilico's AI-driven pipeline portfolio have received IND clearance, with the most advanced being Rentosertib (formerly ISM001-055), a potentially first-in-class drug candidate for idiopathic pulmonary fibrosis, which has completed Phase 2a clinical studies with encouraging results. Additionally, Insilico is exploring exciting new frontiers empowered by AI and automated capabilities, including breakthroughs in aging research, sustainable chemistry, and agricultural innovation.
For more information, please visit www.insilico.com.